We're pleased to announce out newest faculty addition to the Expedition Medicine National Conference: Michael V. Callahan MD DTM&H MSPH.
Dr. Callahan is a well-known expert in the Infectious Disease Division of Massachusetts General Hospital. He has lead numerous research projects in his area of expertise, and from 2005-2012 he led DARPA's $270M biodefense therapeutics program.
Dr. Callahan is a frequent national lecturer and excellent teacher. We're incredibly excited to have Dr. Callahan on our faculty list for the March 9-10, 2018 Expedition Medicine National Confernence in Little Rock. Be sure to register early as space is limited!
Dr. Callahan's full profile:
"Michael Callahan is a physician scientist boarded in medicine, ID, tropical medicine (DTM&H), Mass Casualty Care (DMC) and Rescue Medicine Command MD#17. Dr. Callahan's clinical appointments are at MGH/Harvard Medical School, and Visiting Professor at King Chulalongkorn Medical Center in Bangkok, Kaduna, Nigeria and Panama City, PN. His focus is emergency clinical trials for catastrophic infectious diseases such as Ebola, H5N1, MERS, Zika Virus, Chikungunya and complex dengue viral disease. He has developed drugs in market and expedited Phase 2 trials to support Animal Rule decisions including EUA-OLU trials for H5N1 (Jakarta), H7N9 (Nanjing), cutaneous anthrax (Gombe) burkholderia (Phnom Penh), Ebola (Isiro, Monrovia) and Lassa (Kaduna, Kano). From 2005-2012 he led DARPA's $270M biodefense therapeutics program where he developed multiple drugs in clinic and launched Prophecy, a international physician-to-foreign government clinical trials network to support regulatory decisions for zoonotic and biodefense therapies. In 2010 he was awarded the DARPA Achievement Award, the highest award in the Agency. Biotechnology achievements include: CRP-liposomal amphotericin (Ambisome; Gilead); cPG (Pfizer) MIMIC (Sanofi), pH1N1 vaccine, Nicotinia-expressed Ebola therapies (Leaf/Mapp); 2 vaccines from FSU BW programs and inception, development and funding of DARPA's Accelerated Pharmaceuticals Programs (AMP; 7 INDs; 3 NDAs), 7-Day Biodefense (4 INDs), the MIMIC platform, Rapid Altitude & Hypoxia Acclimatization (ENO; Phase 2),: Prophecy (7 international trial sites) and CLIO (licensing agreement disclosed under CDA). In 2012 Dr. Callahan was recruited as President of Unither Virology a United Therapeutics company (UTHR), leading a R&D team executing a $45M NIH contract to accelerate a antiviral from lead to Phase 2 for dengue and flu, and to develop next-generation antivirals against RSV, Zika, Chikungunya and transplant-associated viral indications."
